Bruker Co. Expected to Post Q3 2024 Earnings of $0.71 Per Share (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Investment analysts at Leerink Partnrs dropped their Q3 2024 EPS estimates for Bruker in a report released on Monday, May 20th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.71 per share for the quarter, down from their prior estimate of $0.78. The consensus estimate for Bruker’s current full-year earnings is $2.73 per share. Leerink Partnrs also issued estimates for Bruker’s Q4 2024 earnings at $0.89 EPS, FY2024 earnings at $2.65 EPS and Q4 2025 earnings at $1.06 EPS.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The business had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. During the same quarter last year, the business earned $0.64 earnings per share. Bruker’s quarterly revenue was up 5.3% compared to the same quarter last year.

Several other research firms have also issued reports on BRKR. JPMorgan Chase & Co. upgraded shares of Bruker from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $60.00 to $90.00 in a report on Wednesday, February 14th. Stifel Nicolaus lowered their target price on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a report on Monday. Bank of America lowered their target price on shares of Bruker from $95.00 to $90.00 and set a “buy” rating for the company in a report on Monday. StockNews.com lowered shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, UBS Group raised their price target on shares of Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $85.00.

Bruker Price Performance

BRKR stock opened at $76.70 on Wednesday. Bruker has a 52 week low of $53.79 and a 52 week high of $94.86. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95. The company has a fifty day simple moving average of $83.53 and a two-hundred day simple moving average of $76.73. The firm has a market capitalization of $11.15 billion, a P/E ratio of 27.89, a price-to-earnings-growth ratio of 2.52 and a beta of 1.22.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 17th. Shareholders of record on Monday, June 3rd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend is Friday, May 31st. Bruker’s dividend payout ratio (DPR) is 7.27%.

Insider Buying and Selling at Bruker

In related news, Director Hermann Fritz Requardt sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the transaction, the director now owns 23,147 shares in the company, valued at approximately $2,084,618.82. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 28.30% of the company’s stock.

Institutional Trading of Bruker

Several large investors have recently bought and sold shares of BRKR. Commonwealth Equity Services LLC grew its position in Bruker by 11.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 13,259 shares of the medical research company’s stock worth $826,000 after purchasing an additional 1,312 shares during the last quarter. Fifth Third Bancorp grew its position in Bruker by 53.3% during the 3rd quarter. Fifth Third Bancorp now owns 541 shares of the medical research company’s stock worth $34,000 after purchasing an additional 188 shares during the last quarter. Duality Advisers LP purchased a new stake in Bruker during the 3rd quarter worth approximately $718,000. California Public Employees Retirement System grew its position in Bruker by 0.4% during the 3rd quarter. California Public Employees Retirement System now owns 200,594 shares of the medical research company’s stock worth $12,497,000 after purchasing an additional 871 shares during the last quarter. Finally, SteelPeak Wealth LLC purchased a new stake in shares of Bruker in the 3rd quarter valued at $487,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.